TMO - Sarepta's Expanded Approval Unlikely To Influence Novo Holdings' Acquisition of Catalent But Provides Investor Protection Amid Uncertainty | Benzinga
Shares of Catalent Inc (NYSE:CTLT), which manufactures Elevidys, are trading higher with a strong session volume of 3.6 million compared to an average volume of 1.6 million.
William Blair notes that Sarepta Therapeutics Inc.’s (NASDAQ:SRPT) Elevidys, supported by its expanded label, is expected to generate approximately $700 million annually in revenue for fiscal years 2025 and 2026, representing a substantial increase from the approximately $425 million generated in fiscal year 2023.
In October 2023, William Blair wrote that in fiscal ...